Press Release
Jun 27, 2024
Growth Represents the Quality of Research and the Speed to Publication for the IASLC’s Official Journals
Contact: Chris Martin, IASLC Media Relations | cmartin@davidjamesgroup.com
(DENVER – June 27, 2024) — The International Association for the Study of Lung Cancer (IASLC) today reported that its main cancer journal, the Journal of Thoracic Oncology (JTO), improved its Impact Factor to 21.0 in 2023, up from 20.1 in 2022. The JTO, the official journal of the IASLC, now ranks second among 100 respiratory medicine journals and 13th among 322 oncology journals.
The JTO Clinical and Research Reports received its first Impact Factor of 3.0, ranking 142 out of 322 oncology journals and 37 out of 100 among respiratory journals. JTO Clinical and Research Reports (JTO CRR) is the official open-access journal of the International Association for the Study of Lung Cancer.
Impact Factors are measured by calculating the number of times journal articles in the two preceding years are cited in a current year. Thus, the 2023 Impact Factor released in 2024 is the number of times articles published in 2021 and 2022 are cited in 2023. The higher the Impact Factor, the more highly ranked the journal. Journal citation reports are issued by Clarivate Analytics.
The JTO is the primary educational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. Emphasizing a multidisciplinary approach, the JTO includes original research, review articles, and opinion pieces. The audience includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, and basic scientists with a special interest in thoracic oncology.
"JTO's impact factor for 2023 has risen to 21, making it only the second respiratory journal (after Lancet Respiratory Medicine) with an impact factor above 20," said Alex A. Adjei, MD, PhD, FACP, Editor-in-Chief of JTO. "More importantly, it is the only thoracic oncology journal with an impact factor greater than 10. This is a notable achievement since we are a sub-specialty journal dealing with only thoracic oncology. There are no other sub-specialty journals among the top 20 oncology journals, and we now rank 13th out of 322 oncology journals. This achievement is a testament to the exemplary work of our editorial board and our editorial office, as well as the support of IASLC—its executives, office staff, membership, and above all, our reviewers, readers, and authors. JTO will continue its emphasis on multidisciplinary research to serve the broad community working in thoracic oncology."
As the companion journal of the JTO, JTO CRR provides a publication hub within the IASLC for research with a more clinical focus and for article types such as case reports, phase 1 and 2 trials, high-impact retrospective studies, and database analyses. The journal offers a gold open-access publication option, which ensures immediate and permanently free access to quality lung cancer studies by everyone.
"The JTO CRR team is celebrating our first impact factor at 3.0, and we wish to thank everyone who made it possible—the authors, reviewers, editors, and the IASLC. We are thrilled to make such a terrific start, which truly reflects our commitment to excellence in science," said Emily Stone, MBBS, PhD, FRACP, and Editor-in-Chief of JTO CRR.
To submit a manuscript or to learn more about the JTO, please visit jto.org. Once there, you can peruse current in-press articles, collections of articles such as the Ninth Edition of TNM Stage Classification of Thoracic Tumors, Controversies in Thoracic Oncology, Lung Cancer Worldwide, and the freely available Editor's Choice articles. The complete contents of the JTO are free for IASLC members. Visit jtocrr.org to learn more.
###
About the IASLC
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 11,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.
About the JTO
Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer, is the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. JTO emphasizes a multidisciplinary approach and includes original research reviews and opinion pieces. The audience includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, nuclear medicine physicians, and research scientists with a special interest in thoracic oncology.
About the JTO CRR
JTO Clinical and Research Reports is the official open-access journal of the International Association for the Study of Lung Cancer. It aims to complement the Journal of Thoracic Oncology by offering authors a gold open-access publication option and publishing the following article types in particular: phase I trials, well-performed single-arm phase II trials, subset analyses of published trials, impactful retrospective studies, database analysis, large institutional series, high-quality case reports, region-specific clinical trials, subspecialty thoracic oncology studies and selected high-quality meeting reports.